GLP-1RAs Linked to Reduced Disease Activity and Cardiovascular Risks in RA
The use of GLP-1RAs may improve RA disease activity and cardiovascular risk profiles among patients with overweight or obesity.
According to a study published in ACR Open Rheumatology, rheumatoid arthritis (RA) disease activity and cardiovascular risk factors can be improved by the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) among patients with overweight or obesity.
Rheumatoid arthritis often coexists with obesity, leading to increased inflammation, greater disease activity, and lower response to therapy.
- GLP-1RAs are established for obesity, type 2 diabetes, and cardiovascular risk reduction.
- Their role in RA has not been well defined until now.
A single-center, retrospective observational study was conducted at the University of California, Los Angeles, including patients with RA and a body mass index (BMI) of at least 27 kg/m2.
No direct quote available in the text.
Author's summary: GLP-1RAs reduce disease activity and cardiovascular risks in RA patients with overweight or obesity.
More News
- Leonardo DiCaprio Steps Out With Dad and Stepmom in Rare Appearance
- Leonardo – Shaping the Future of Global Security and Innovation
- Leonardo DiCaprio's stepmom and dad steal the show
- George Russell Stuns Title Contenders to Top Decisive FP3
- 3 Million for One Day… Yet DiCaprio Said No: The Actor Refuses the Most Anticipated Sequel of His Career
- Leonardo DiCaprio – biographie
- George Russell: Older me can’t envy Lando Norris’ F1 title, he deserves it
- College Football Playoff Rankings LIVE SHOW | Reveal …
- 'Not fair' - Russell criticises McLaren's Abu Dhabi team order stance
- Clever George Russell trick emerges after Max Verstappen ...